Skip to main content
Erschienen in: Cancer Causes & Control 12/2010

01.12.2010 | Original paper

Comprehensive cancer control: progress and accomplishments

verfasst von: Phyllis W. Rochester, Julie S. Townsend, Leslie Given, Hope Krebill, Sandra Balderrama, Cynthia Vinson

Erschienen in: Cancer Causes & Control | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

The potential for Comprehensive Cancer Control (CCC) across the nation has been realized in the last decade with 69 Coalitions developing and implementing CCC plans. Many partners at all levels—national, state, jurisdictional, tribal and communities—have contributed to this success. This article details the contribution of these partners across these various levels, with a selection of the many activities contributing to this success. Consequently the cancer burden, although still of major importance, continues to be addressed in significant ways. Although there are future challenges, CCC coalitions continue to play an important role in addressing the cancer burden.
Literatur
1.
Zurück zum Zitat Given LS, Black B, Lowry G, Huang P, Kerner JF (2005) Collaborating to conquer cancer: a comprehensive approach to cancer control. Cancer Causes Control 16(suppl 1):3–14CrossRefPubMed Given LS, Black B, Lowry G, Huang P, Kerner JF (2005) Collaborating to conquer cancer: a comprehensive approach to cancer control. Cancer Causes Control 16(suppl 1):3–14CrossRefPubMed
2.
3.
Zurück zum Zitat Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK (1998) Cancer incidence and mortality, 1973–1995: a report card for the U.S. Cancer 82:1197–1207CrossRefPubMed Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK (1998) Cancer incidence and mortality, 1973–1995: a report card for the U.S. Cancer 82:1197–1207CrossRefPubMed
4.
Zurück zum Zitat Sutherland JE, Persky VW, Brody JA (1990) Proportionate mortality trends: 1950 through 1986. JAMA 264:3178–3184CrossRefPubMed Sutherland JE, Persky VW, Brody JA (1990) Proportionate mortality trends: 1950 through 1986. JAMA 264:3178–3184CrossRefPubMed
5.
Zurück zum Zitat Goodman RM, Steckler A, Alciati MH (1997) A process evaluation of the National Cancer Institute’s Data-based Intervention Research Program. Health Educ Res 12(2):181–197CrossRefPubMed Goodman RM, Steckler A, Alciati MH (1997) A process evaluation of the National Cancer Institute’s Data-based Intervention Research Program. Health Educ Res 12(2):181–197CrossRefPubMed
6.
Zurück zum Zitat Abed J, Reilley B, Butler MO et al (2000) Developing a framework for comprehensive cancer prevention and control in the United States: an initiative of the Centers for Disease Control and Prevention. Public Health Manag Pract 6:67–78 Abed J, Reilley B, Butler MO et al (2000) Developing a framework for comprehensive cancer prevention and control in the United States: an initiative of the Centers for Disease Control and Prevention. Public Health Manag Pract 6:67–78
7.
Zurück zum Zitat La Porta M, Hagood H, Kornfeld J, Treiman K (2007) Partnership as a means for reaching special populations: Evaluating the NCI’s CIS Partnership Program. J Cancer Educ 22(Suppl):S35–S40CrossRefPubMed La Porta M, Hagood H, Kornfeld J, Treiman K (2007) Partnership as a means for reaching special populations: Evaluating the NCI’s CIS Partnership Program. J Cancer Educ 22(Suppl):S35–S40CrossRefPubMed
9.
Zurück zum Zitat Edwards BK, Ward E, Kohler BA et al (2010) Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544–573CrossRefPubMed Edwards BK, Ward E, Kohler BA et al (2010) Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544–573CrossRefPubMed
10.
Zurück zum Zitat Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. The Oncologist 12:20–37CrossRefPubMed Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. The Oncologist 12:20–37CrossRefPubMed
11.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2009 Sub (1973–2007 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission Surveillance, Epidemiology, and End Results (SEER) Program (www.​seer.​cancer.​gov) SEER*Stat Database: Incidence—SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2009 Sub (1973–2007 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission
Metadaten
Titel
Comprehensive cancer control: progress and accomplishments
verfasst von
Phyllis W. Rochester
Julie S. Townsend
Leslie Given
Hope Krebill
Sandra Balderrama
Cynthia Vinson
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 12/2010
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9657-8

Weitere Artikel der Ausgabe 12/2010

Cancer Causes & Control 12/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.